Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

131.91 +0.24 (+0.18%)
Streaming Delayed Price Updated: 2:05 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Nasdaq Down Over 1%; Foot Locker Shares Tumble After Q2 Results ↗
 
Via Benzinga
News headline image
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors ↗
Neurocrine Biosciences reports Phase 2 trial results for NBI-1117568 showing significant improvement in schizophrenia symptoms, with an 18.2-point reduction in PANSS scores at a 20 mg dose. 
Via Benzinga
News headline image
US Stocks Mixed; JM Smucker Slashes Annual Guidance ↗
 
Via Benzinga
News headline image
Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers ↗
As new schizophrenia drugs move toward approval, Neurocrine Biosciences reports a subpar outcome for its phase 2 trial. 
Via Investor's Business Daily
News headline image
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna ↗
Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomberg reports. 
Via Benzinga
News headline image
Evaluating Neurocrine Biosciences: Insights From 15 Financial Analysts ↗
 
Via Benzinga
News headline image
NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?. 
Via Chartmill
News headline image
NASDAQ:NBIX is not too expensive for the growth it is showing. ↗
Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
News headline image
Why the quality investor may take a look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). ↗
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) suited for quality investing? 
Via Chartmill
News headline image
9 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
New Study Reveals How Classical Music Could Revolutionize Depression Care
In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of... 
Via PressReach
News headline image
So Much For Expecting The Fed To Stick The Landing ↗
Now is not the time to be fully invested. 
Via Talk Markets
Topics Economy
News headline image
A Closer Look at 7 Analyst Recommendations For Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
NASDAQ:NBIX, a strong growth stock, setting up for a breakout. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?. 
Via Chartmill
News headline image
NASDAQ:NBIX, a growth stock which is not overvalued. ↗
Looking for growth without the hefty price tag? Consider NASDAQ:NBIX. 
Via Chartmill
News headline image
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review ↗
Apple and Meta had strong results, while AI spending remains robust. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
Should Quality Investors Include NASDAQ:NBIX in Their Portfolio? ↗
Why Quality Investors May Find NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Attractive. 
Via Chartmill
News headline image
Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), a strong growth stock, setting up for a breakout. 
Via Chartmill
News headline image
Key Takeaways From Neurocrine Biosciences Analyst Ratings ↗
 
Via Benzinga
News headline image
Exploring NASDAQ:NBIX's quality characteristics. ↗
Reasonable growth and debt and a high ROIC for NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). 
Via Chartmill
News headline image
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) qualifies as a high growth stock and is consolidating. 
Via Chartmill
News headline image
NASDAQ:NBIX is not too expensive for the growth it is showing. ↗
Don't overlook NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
News headline image
Reasonable Growth, Debt Levels, and a High ROIC Make NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Appealing to Quality Investors. ↗
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) qualifies as a quality stock. 
Via Chartmill
News headline image
Despite its impressive fundamentals, NASDAQ:NBIX remains undervalued. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), an undervalued stock with good fundamentals. 
Via Chartmill
News headline image
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline ↗
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
Via InvestorPlace
News headline image
Is NASDAQ:NBIX on the Verge of a Major Breakout as a Strong Growth Stock? ↗
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
News headline image
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans ↗
Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas. 
Via Investor's Business Daily
News headline image
In the world of growth stocks, NASDAQ:NBIX shines as a value proposition. ↗
Looking for growth without the hefty price tag? Consider NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). 
Via Chartmill
News headline image
Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation. ↗
Investors should take note ofNEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), a growth stock that remains attractively priced. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>